🌟 99% Happy customers

📦 Same-day shipping on in-stock items

Catalog Number:
29275
CAS Number:
1132662-08-8
Capecitabina-D11
Documents
Available - Request Bulk Quote
Tamaño
Request Bulk Quote
Product Information

Capecitabine-D11 is a deuterated analog of the well-known chemotherapeutic agent Capecitabine, designed to enhance the pharmacokinetic properties and metabolic stability of the parent compound. This compound is particularly relevant in oncology research, where it serves as a valuable tool for studying drug metabolism and efficacy in cancer treatment. The incorporation of deuterium can lead to improved drug performance, potentially reducing side effects and enhancing therapeutic outcomes.

Researchers in pharmaceutical development can utilize Capecitabine-D11 for various applications, including metabolic studies, formulation development, and the investigation of drug interactions. Its unique isotopic labeling allows for precise tracking in biological systems, making it an essential compound for studies focused on drug absorption, distribution, metabolism, and excretion (ADME). By leveraging the benefits of Capecitabine-D11, professionals can gain deeper insights into the pharmacological profiles of cancer therapies, ultimately contributing to the advancement of effective treatment strategies.

CAS Number
1132662-08-8
Molecular Formula
C15H11D11FN3O6
Molecular Weight
370.42
MDL Number
MFCD10567126
PubChem ID
400633
Conditions
Conservar entre 0 y 8 °C.
General Information
CAS Number
1132662-08-8
Molecular Formula
C15H11D11FN3O6
Molecular Weight
370.42
MDL Number
MFCD10567126
PubChem ID
400633
Conditions
Conservar entre 0 y 8 °C.
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Capecitabine-D11 is widely utilized in research focused on:

  • Pharmaceutical Development: This compound is crucial in the development of targeted cancer therapies, particularly for colorectal and breast cancers. Its isotopic labeling allows researchers to track metabolic pathways and drug interactions effectively.
  • Clinical Trials: Used in clinical studies to evaluate the efficacy and safety of new cancer treatments, Capecitabine-D11 helps in understanding the pharmacokinetics of the drug, providing insights into how it behaves in the human body.
  • Metabolomics: This compound plays a significant role in metabolomics studies, where it aids in identifying biomarkers for cancer progression and treatment response, enhancing personalized medicine approaches.
  • Radiolabeling Techniques: Capecitabine-D11 can be employed in radiolabeling for imaging studies, allowing for non-invasive monitoring of drug distribution and tumor targeting in preclinical models.
  • Research on Drug Resistance: It is instrumental in studies investigating mechanisms of drug resistance in cancer cells, helping researchers develop strategies to overcome resistance and improve treatment outcomes.

Citas